← Eichor
Condition: Ebv Positive Lymphoma Synced from ClinicalTrials.gov · July 29, 2026

Recruiting studies: Ebv Positive Lymphoma

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

MCW Alpha/Beta T-Cell and B-Cell Depletion With Targeted ATG Dosing
NA · 1 location(s) · Medical College of Wisconsin · NCT05794880EBV Specific T-Lymphocytes for Treatment of EBV-Positive Lymphoma
Phase 1 · 4 location(s) · Baylor College of Medicine · NCT04664179A Study of CD19 Targeted CAR T Cell Therapy in Pediatric Patients With Relapsed or Refractory B Cell Acute Lymphoblastic
Phase 1 · 8 location(s) · Autolus Limited · NCT06173518Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders
Phase 2 · 1 location(s) · Masonic Cancer Center, University of Minnesota · NCT03314974Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution
Phase N/A · 5 location(s) · Children's Hospital Medical Center, Cincinnati · NCT06131801Nivolumab in Epstein-Barr Virus (EBV)-Positive Lymphoproliferative Disorders and EBV-Positive Non-HodgkinLymphomas
Phase 2 · 1 location(s) · National Cancer Institute (NCI) · NCT03258567Study of KTE-X19 in Minimal Residual Disease (MRD) Positive B-Cell Acute Lymphoblastic Leukemia (B-ALL)
Phase 2 · 1 location(s) · H. Lee Moffitt Cancer Center and Research Institute · NCT06144606ABL001 + Dasatinib + Prednisone + Blinatumomab in BCR-ABL+ B-ALL or CML
Phase 1 · 4 location(s) · Marlise Luskin, MD · NCT03595917Constitutive IL7R (C7R) Modified Banked Allogeneic CD30.CAR EBVSTS for CD30-Positive Lymphomas
Phase 1 · 2 location(s) · Baylor College of Medicine · NCT06176690Registry of Older Patients With Cancer
Phase N/A · 7 location(s) · UNC Lineberger Comprehensive Cancer Center · NCT01137825Allogeneic CD30.CAR-EBVSTs in Patients With Relapsed or Refractory CD30-Positive Lymphomas
Phase 1 · 2 location(s) · Baylor College of Medicine · NCT04288726Golcadomide and Rituximab as Bridging Therapy for Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma Before C
Phase 2 · 7 location(s) · Mayo Clinic · NCT06834373A Registry for People With T-cell Lymphoma
Phase N/A · 26 location(s) · Memorial Sloan Kettering Cancer Center · NCT059781413'-Deoxy-3'-[18F] Fluorothymidine PET Imaging in Patients With Cancer
Phase N/A · 1 location(s) · Barbara Ann Karmanos Cancer Institute · NCT00935090Clinical Study of SYNCAR-100 in the Treatment of Relapsed/Refractory Acute B-Lymphoblastic Leukemia
EARLY_Phase 1 · 1 location(s) · Zhejiang University · NCT07429461A Clinical Study Evaluating the Safety and Efficacy of GT801 Injection in Adult Patients With Relapsed/Refractory CD19-p
EARLY_Phase 1 · 2 location(s) · Grit Biotechnology · NCT07205315Epcoritamab With Dose Adjusted Etoposide, Cyclophosphamide, Vincristine, Doxorubicin, Prednisone and Rituximab (EPOCH-R)
Phase 2 · 1 location(s) · University of Washington · NCT07097363Inotuzumab Ozogamicin and Blinatumomab With or Without Ponatinib in Treating Patients With Newly Diagnosed, Recurrent, o
Phase 2 · 278 location(s) · National Cancer Institute (NCI) · NCT03739814CAR-T-19 Injection in the Treatment of CD19-positive Relapsed/Refractory B-ALL
Phase 2 · 1 location(s) · Beijing Yongtai Ruike Biotechnology Company Ltd · NCT06179524Donor Stem Cell Transplant With Treosulfan, Fludarabine, and Total-Body Irradiation for the Treatment of Hematological M
Phase 2 · 1 location(s) · Fred Hutchinson Cancer Center · NCT04195633Recombinant Erwinia Asparaginase and Venetoclax in Combination With Blinatumomab for the Treatment of Relapsed or Refrac
Phase 1 · 1 location(s) · City of Hope Medical Center · NCT07133997Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)
Phase 1/Phase 2 · 9 location(s) · Vironexis Biotherapeutics Inc. · NCT06533579EBV-AST Cell Injection for EBV-Associated Lymphoproliferative Disorders
Phase 1/Phase 2 · 1 location(s) · Daihong Liu · NCT07450391Cytotoxic T-Lymphocytes for EBV-positive Lymphoma, GRALE
Phase 1 · 3 location(s) · Baylor College of Medicine · NCT01555892CD180 CART for Relapsed or Refractory CD180 Positive Hematologic Malignancies
Phase 1 · 1 location(s) · Institute of Hematology & Blood Diseases Hospital, China · NCT07106749Tissue, Blood, and Body Fluid Sample Collection From Patients With Hematologic Cancer
Phase N/A · 1 location(s) · UNC Lineberger Comprehensive Cancer Center · NCT01137643Allo HSCT Using RIC and PTCy for Hematological Diseases
Phase 2 · 1 location(s) · Masonic Cancer Center, University of Minnesota · NCT05805605Clinical Study of Hospital-manufactured CD19 CAR-T in Children and Adolescents With Acute Lymphoblastic Leukemia
Phase 1 · 1 location(s) · Seoul National University Hospital · NCT05210907A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adole
Phase 2 · 155 location(s) · National Cancer Institute (NCI) · NCT06124157Pembro Plus CAR T-cell Therapy in R/R in PMBCL
Phase 2 · 2 location(s) · Jennifer Crombie, MD · NCT05934448
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.